[1] |
Yin L,Duan JJ,Bian XW,et al. Triple-negative breast cancer molecular subtyping and treatment progress[J]. Breast Cancer Res,2020,22(1):61.
|
[2] |
Hwang SY,Park S,Kwon Y. Recent therapeutic trends and promising targets in triple negative breast cancer[J]. Pharmacol Ther,2019,199:30-57.
|
[3] |
Manjunath M,Choudhary B. Triple-negative breast cancer:A run-through of features,classification and current therapies[J]. Oncol Lett,2021,22(1):512.
|
[4] |
Wu HT,Lin J,Liu YE,et al. Luteolin suppresses androgen receptor-positive triple-negative breast cancer cell proliferation and metastasis by epigenetic regulation of MMP9 expression via the AKT/mTOR signaling pathway[J]. Phytomedicine,2021,81:153437.
|
[5] |
Kwapisz D. Pembrolizumab and atezolizumab in triple-negative breast cancer[J]. Cancer Immunology,2021,70(3):607-617.
|
[6] |
朱荔,王建东. 免疫检查点抑制剂在乳腺癌免疫治疗中应用进展[J]. 中国实用外科杂志,2021,41(11):1297-1303.
|
[7] |
Emens LA,Adams S,Barrios CH,et al. First-line atezolizumab plus nab-paclitaxel for unresectable,locally advanced,or metastatic triple-negative breast cancer:IMpassion130 final overall survival analysis[J]. Ann Oncol,2021,32(8):983-993.
|
[8] |
Basch E,Becker C,Rogak LJ,et al. Composite grading algorithm for the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events(PRO-CTCAE)[J]. Clin Trials,2021,18(1):104-114.
|
[9] |
Emens LA,Adams S,Barrios CH,et al. First-line atezolizumab plus nab-paclitaxel for unresectable,locally advanced,or metastatic triple-negative breast cancer:IMpassion130 final overall survival analysis[J]. Ann Oncol,2021,32(8):983-993.
|
[10] |
Basch E,Becker C,Rogak LJ,et al. Composite grading algorithm for the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events(PRO-CTCAE)[J]. Clin Trials,2021,18(1):104-114.
|
[11] |
Schmid P,Adams S,Rugo HS,et al. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer[J]. N Engl J Med,2018,379(22):2108-2121.
|
[12] |
Mittendorf EA,Zhang H,Barrios CH,et al. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer(IMpassion031):a randomised,double-blind,phase 3 trial[J]. Lancet,2020,396(10257):1090-1100.
|
[13] |
Cortes J,Cescon DW,Rugo HS,et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer(KEYNOTE-355):a randomised,placebo-controlled,double-blind,phase 3 clinical trial[J]. Lancet,2020,396(10265):1817-1828.
|
[14] |
Miles D,Gligorov J,André F,et al. Primary results from IMpassion131,a double-blind,placebo-controlled,randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer[J]. Ann Oncol,2021,32(8):994-1004.
|
[15] |
Iwata H,Inoue K,Kaneko K,et al. Subgroup analysis of Japanese patients in a Phase 3 study of atezolizumab in advanced triple-negative breast cancer(IMpassion130)[J]. Jpn J Clin Oncol,2019,49(12):1083-1091.
|
[16] |
虞小亭,刘正人,谢熠,等. 肝细胞生长因子在乳腺癌新辅助化疗前后的变化及其临床意义[J/CD]. 中华普外科手术学杂志(电子版),2021,15(03):306-309.
|
[17] |
崔志超,马杰,王雅琪,等. HER2阳性乳腺癌患者新辅助化疗后免疫分型变化的研究[J/CD]. 中华普外科手术学杂志(电子版),2020,14(02):189-192.
|
[18] |
中国抗癌协会乳腺癌专业委员会. 中国抗癌协会乳腺癌诊治指南与规范(2021年版)[J]. 中国癌症杂志,2021,31(10):954-1040.
|
[19] |
Ai L,Xu A,Xu J. Roles of PD-1/PD-L1 Pathway:Signaling,Cancer,and Beyond[J]. Adv Exp Med Biol,2020,1248:33-59.
|
[20] |
林少妍,马飞,徐兵河. PD-1/PD-L1抑制剂在三阴性乳腺癌治疗中的研究进展[J]. 临床药物治疗杂志,2018,16(07):7-10.
|
[21] |
Emens LA. Immunotherapy in Triple-Negative Breast Cancer[J]. Cancer J,2021,27(1):59-66.
|
[22] |
Kwapisz D. Pembrolizumab and atezolizumab in triple-negative breast cancer[J]. Cancer Immunol Immunother,2021,70(3):607-617.
|
[23] |
李健斌,江泽飞. 2021年中国临床肿瘤学会乳腺癌诊疗指南更新要点解读[J]. 中华医学杂志,2021,101(24):1835-1838.
|
[24] |
Andrews LP,Yano H,Vignali DAA. Inhibitory receptors and ligands beyond PD-1,PD-L1 and CTLA-4:breakthroughs or backups[J]. Nat Immunol,2019,20(11):1425-1434.
|
[25] |
Hall PE,Schmid P. Emerging drugs for the treatment of triple-negative breast cancer:a focus on phase II immunotherapy trials[J]. Expert Opin Emerg Drugs,2021,26(2):131-147.
|
[26] |
Keenan TE,Tolaney SM. Role of Immunotherapy in Triple-Negative Breast Cancer[J]. J Nat Compr Canc Netw,2020,18(4):479-489.
|